PL1559431T3 - Kompozycja farmaceutyczna dla pochodnych peptydu trombiny - Google Patents

Kompozycja farmaceutyczna dla pochodnych peptydu trombiny

Info

Publication number
PL1559431T3
PL1559431T3 PL04258191T PL04258191T PL1559431T3 PL 1559431 T3 PL1559431 T3 PL 1559431T3 PL 04258191 T PL04258191 T PL 04258191T PL 04258191 T PL04258191 T PL 04258191T PL 1559431 T3 PL1559431 T3 PL 1559431T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
thrombin peptide
peptide derivatives
thrombin
disclosed
Prior art date
Application number
PL04258191T
Other languages
English (en)
Inventor
David M Hobson
Roger S Crowther
Darrell H Carney
Andrew Po Kwan Tang
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of PL1559431T3 publication Critical patent/PL1559431T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
PL04258191T 2003-12-31 2004-12-30 Kompozycja farmaceutyczna dla pochodnych peptydu trombiny PL1559431T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53373003P 2003-12-31 2003-12-31
EP04258191A EP1559431B1 (en) 2003-12-31 2004-12-30 Pharmaceutical composition for thrombin peptide derivatives

Publications (1)

Publication Number Publication Date
PL1559431T3 true PL1559431T3 (pl) 2007-10-31

Family

ID=34652502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04258191T PL1559431T3 (pl) 2003-12-31 2004-12-30 Kompozycja farmaceutyczna dla pochodnych peptydu trombiny

Country Status (13)

Country Link
US (2) US7291596B2 (pl)
EP (1) EP1559431B1 (pl)
JP (1) JP5044829B2 (pl)
CN (1) CN1913917B (pl)
AT (1) ATE357928T1 (pl)
AU (1) AU2004312090B2 (pl)
CA (1) CA2551525C (pl)
DE (1) DE602004005564T2 (pl)
DK (1) DK1559431T3 (pl)
ES (1) ES2287660T3 (pl)
PL (1) PL1559431T3 (pl)
PT (1) PT1559431E (pl)
WO (1) WO2005065706A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362939T1 (de) * 2002-07-02 2007-06-15 Orthologic Corp Dimere von thrombinpeptidderivaten
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US8334259B2 (en) * 2006-09-22 2012-12-18 The Board Of Regents, The University Of Texas System Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
CA2719940A1 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
WO2010033862A2 (en) * 2008-09-19 2010-03-25 The Board Of Regents, The University Of Texas System Methods for treating cancer
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2539435A2 (en) 2010-02-23 2013-01-02 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US11019824B2 (en) * 2013-10-03 2021-06-01 Luis Alberto Amestica Salazar Biocidal resin composition including one or a plurality of resins selected from MF, UF, PF, MUF and phenolic resins; and more than one soluble copper salt
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CN105879010A (zh) * 2015-01-17 2016-08-24 内蒙古天奇生物科技有限公司 一种能促进创伤愈合减轻创后瘢痕的多肽组合物及其制备方法
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
WO2020210087A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions
JP2023139750A (ja) * 2022-03-22 2023-10-04 株式会社東芝 抗酸化剤を用いたｆｅｔセンサ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019612A1 (de) * 1980-05-22 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Stabilisiertes thrombinpraeparat
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JP2000229882A (ja) * 1998-12-10 2000-08-22 Sankyo Co Ltd 修飾シクロデキストリン含有トロンビン水性液剤
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
TR200400260T4 (tr) * 2000-07-19 2004-03-22 The Board Of Regents, The University Of Texas System Trombin peptid türevleri ile kemik büyümesinin uyarılması
DE60105772T2 (de) * 2000-07-20 2006-02-16 Board of Regents, The University of Texas System, Austin Stimulation des knorpelwachstums mit agonisten des nicht-proteolytisch aktivierten thrombin rezeptors
EP1333824B1 (en) * 2000-11-17 2005-09-07 Warner-Lambert Company LLC Treatment of sexual dysfunction with bombesin receptor antagonists
EP1366075B1 (en) * 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
DE60212143T2 (de) 2001-07-27 2007-04-12 Orthologic Corp., Tempe Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera
JP4205592B2 (ja) 2002-01-16 2009-01-07 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 心臓組織修復を促進するためのトロンビン由来ペプチド
JP2005519067A (ja) 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
JP5184738B2 (ja) * 2002-05-03 2013-04-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 修飾第ｖｉｉ因子の安定化された固体組成物
EP1539214A4 (en) * 2002-07-02 2008-01-02 Orthologic Corp Thrombin
ATE362939T1 (de) * 2002-07-02 2007-06-15 Orthologic Corp Dimere von thrombinpeptidderivaten

Also Published As

Publication number Publication date
HK1080390A1 (en) 2006-04-28
JP2007518724A (ja) 2007-07-12
WO2005065706A1 (en) 2005-07-21
EP1559431B1 (en) 2007-03-28
US20050203017A1 (en) 2005-09-15
JP5044829B2 (ja) 2012-10-10
US7875588B2 (en) 2011-01-25
US7291596B2 (en) 2007-11-06
CN1913917B (zh) 2012-02-01
EP1559431A1 (en) 2005-08-03
ATE357928T1 (de) 2007-04-15
AU2004312090A1 (en) 2005-07-21
AU2004312090B2 (en) 2008-08-14
PT1559431E (pt) 2007-07-02
DE602004005564T2 (de) 2007-12-13
CA2551525C (en) 2013-02-19
DK1559431T3 (da) 2007-07-30
CA2551525A1 (en) 2005-07-21
CN1913917A (zh) 2007-02-14
DE602004005564D1 (de) 2007-05-10
US20090054343A1 (en) 2009-02-26
ES2287660T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
DK1559431T3 (da) Farmaceutisk sammensætning til thrombinpeptidderivater
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
IL176452A0 (en) Effervescent oral opiate dosage form
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2003072195A3 (en) Method for administering glp-1 molecules
NO20013469L (no) Fremgangsmåter for glukagonsuppresjon
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
WO2004032866A3 (en) Therapeutic formulations
PL374443A1 (pl) Nowe pochodne pirymidynoamidów oraz ich zastosowanie
PL370914A1 (pl) Środki farmaceutyczne i sposoby podawania selektywnych agonistów receptora EP2
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
WO2004041190A3 (en) Composition for the treatment of macular degenration
AU2003290015A1 (en) Mastitis treatment
WO2005048993A3 (en) Minimization of drug oxidation in drug irradiated excipients formulations
AU2003251643A1 (en) Pharmaceutical compositions containing keto-acids for endoperitoneal administration
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
EP1260221A3 (en) Combination treatment for depression and anxiety